Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)
Cancer
INDICATION: Brain cancer
Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22-LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain